IABCR 2023: 32nd International Association for Breast Cancer Research Conference

IABCR 2023: 32nd International Association for Breast Cancer Research Conference is organized by Fusion Conferences Ltd and will be held from May 01 - 04, 2023 at Hilton Tulum Riviera Maya, Riviera Maya, Quintana Roo, Mexico.

Description:
A breast cancer diagnosis is now the most frequent cancer found around the globe. The Estrogen Receptor (ER) transcriptional pathway is responsible for the development of most breast cancers; recent discoveries regarding how the ER regulates gene expression have uncovered numerous therapeutic targets. The core treatment strategies for ER-positive breast cancers are endocrine therapies, which either disrupt the transactivation of ER or reduce the amount of ER present intracellularly. However, intrinsic and acquired resistance limits the clinical efficacy of these therapies, making them less effective overall.

A scientific understanding of the various subtypes of breast cancer has not only offered exceptional insight into the disease's inherent heterogeneity. Still, it has also shown critical processes related to the course of the disease and the patient's response to treatment. These relatively recent developments in our understanding of breast cancer subtypes have led to the creation of individualized treatment plans for distinct patient subpopulations, which has led to an increase in the overall survival rate.

The treatment of breast cancer has been revolutionized due to the emergence of more recent therapies that target the ER pathway (for example, CDK4/6 inhibitors that target a downstream target gene of the ER pathway). Recent research into the interaction between the estrogen receptor (ER) and other nuclear receptor transcription factors, such as the androgen receptor (AR), the progesterone receptor (PR), and the glucocorticoid receptor (GR), has led to the discovery of novel therapeutic opportunities for inhibiting ER activity through the activation of parallel nuclear receptor pathway competitions.

The treatment responses of individuals with HER2+ disease have significantly improved due to more recent breakthroughs in HER2-targeted medicines for the treatment of HER2+ malignancies. Our understanding of Triple Negative Breast Cancer (TNBC) has generally lagged behind our understanding of other subtypes of the disease; however, significant recent new insights into the genetic perturbations and the associations with specific treatment responses have shed light on this subtype of the disease.

Our understanding of breast cancer has been fundamentally altered by genomic and transcriptomic research, which has inspired the development of novel diagnostic and treatment approaches. Our understanding of breast cancers has been revolutionized by more recent advancements in single-cell RNA sequencing (scRNA-seq) and spatial imaging technologies, which have provided insight into complex cellular ecosystems that continuously interact to govern tumor progression and treatment outcome. These technologies have also provided new research opportunities. New computational approaches have made the development of spatial maps of breast cancers at single-cell resolution possible. These maps include immune cell populations and their interactions with stromal and tumor cells. These maps provide unique biological and mechanistic insights into the tumor microenvironment and its role in disease progression, treatment response, and resistance.

Experts in the field who investigate the biological basis of breast cancer, devise methods for patient stratification, conduct clinical trials, or create new treatments for patients with breast cancer will participate in this meeting. 

Key Sessions:
• New molecular insight into breast cancer
• Contemporary models of breast cancer
• Spatial relationships between molecules and cell types
• What are the molecular events that drive metastasis
• Harnessing the immune system 
• How do we position new treatments in the therapeutic spectrum

Confirmed Speakers:
• Cheryl Arrowsmith (University of Toronto)
• Christine Chaffer (Garvan Institute)
• Sarat Chandarlapaty (Memorial Sloan Kettering Cancer Center)
• Christina Curtis (Stanford Medicine)
• Melissa Davis (Walter and Eliza Hall Institute of Medical Research)
• Geoffrey Greene (University of Chicago)
• Theresa Hickey (University of Adelaide)
• Katherine Hoadley (the University of North Carolina at Chapel Hill)
• Walid Khaled (University of Cambridge)
• Simon Knott (Cedars-Sinai)
• Weibo Luo (University of Texas Southwestern Medical Center)
• Mathieu Lupien (University Health Network)
• Luca Magnani (Imperial College London)
• Ciara Metcalfe (Genentech)
• Bill Muller (McGill University)
• Senthil Muthuswamy (Dana-Farber / Harvard Cancer Center)
• Neal Rosen (Memorial Sloan Kettering Cancer Center)
• Carol Sartorius (University of Colorado Anschutz Medical Campus)
• Elinor Sawyers (King's College London)
• Rachel Schiff (Baylor College of Medicine)
• Violeta Serra (Vall d'Hebron Institute of Oncology)
• Alex Swarbrick (Garvan Institute)
• Céline Vallot (Institut Curie)
• Valerie Weaver (University of California, San Francisco)
• Leonie Young (Royal College of Surgeons in Ireland)
• Wilbert Zwart (Netherlands Cancer Institute)

Student Offer:
Take advantage of this fantastic opportunity for students and postdocs! Fully paying academics can bring a student for only $990. Both registration packages include; accommodation for the 01, 02, and 03 May 2023 (on a shared basis for students/postdocs) and an all-inclusive food and beverage package for the conference period. Once registered, please contact Fusion directly to obtain a special registration link for your student.